Medistim ASA (FRA:MD1) Moat Score: 0/10 (As of Jul. 06, 2026)


FRA:MD1 Medistim ASA FRA:MD1
100 GF Score
Price €19.90
GF Value €23.04
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Moat Score?

Medistim ASA has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Medistim ASA has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medistim ASA might have No Moat - No discernible moat.

Medistim ASA  (FRA:MD1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medistim ASA Moat Score Related Terms

FRA:MD1
100GF Score
Medistim ASA FRA:MD1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medistim ASA (FRA:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €19.90 is trading 13.6% below its estimated GF Value™ of €23.04. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for FRA:MD1:

  • Moat Score: 0
  • GF Value™: €23.04 vs. price of €19.90 (13.6% below fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score

Get the complete analysis for FRA:MD1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.90
Price
€23.04
GF Value